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One step synthesis of 2,3-dihydroquinazolin-4(1H)-ones from gem-dibromomethylarenes using 2-
aminobenzamide is described. Gem-dibromomethylarenes are used as aldehyde equivalent for the
eﬃcient synthesis of 2,3-dihydroquinazolin-4(1H)-ones, this synthesis takes shorter reaction time with
quick isolation and excellent product yield.Introduction
Quinazolinone derivatives have drawn considerable attention
due to their antidepressant,1a analgesic,1b diuretic,1c anti-
histamine,2a vasodilating,2b antihypertensive,2c and anti-
inammatory activities.3 They also possess anticancer4 activi-
ties like inhibition of tubulin formation,5,6 inhibition against
VEGFR2 tyrosine kinase and cell proliferation.7 These N-
containing heterocyclic compounds are integral part of many
drug molecules and several classical methods for the synthesis
of 2,3-dihydroquinazoline-4(1H)-ones are available.8–15
Many transition metals like Sc, Ti, Co, Cu, Zn, Zr, and Ru are
used in the synthesis of 2,3-dihydroquinazoline-4(1H)-ones.16a–g
In addition, gem-dibromomethylarenes are used as aldehyde
equivalent in the synthesis of cinnamic acids,17a cinnamic
esters,17b benzimidazoles,18a benzothiazoles18b and aryl oxi-
mes.18c In continuation of our studies18a,b,c (Scheme 1), we tried
using gem-dibromomethylarenes for the synthesis of 2,3-dihy-
droquinazoline-4(1H)-ones.romomethylarenes as aldehyde
niversity of Mysore, Manasagangotri,
ks@gmail.com; rangappaks@chemistry.
l: +91-821-2419661
tion (ESI) available. See DOI:
hemistry 2014We investigated model reaction between 2-aminobenzamide
and gem-dibromomethylarenes under diﬀerent conditions, and
the results are presented in Table 1.Results and discussion
The synthesis of gem-dibromomethylarenes was initiated from
the corresponding commercially available methyl analogues
using N-bromo succinamide (2.0 equiv.) in carbon tetrachloride
with a catalytic amount of benzoyl peroxide (0.2 equiv.) under
reux conditions. A mixture of 1-chloro-3-(dibromomethyl)
benzene 1a (1.0 equiv), 2-aminobenzamide 2a (1.1 equiv.),
potassium tert-butoxide (t-BuOK) (0.5 equiv.) in anhydrous
pyridine and dimethylformamide (3 : 1 ratio) solvent was stir-
red at room temperature, but only trace amount of product was
obtained even aer 6 h of stirring (entry 1, Table 1). Improve-
ment in product yield (entry 2, Table 1) was achieved when the
reaction mixture was heated at 80 C for 6 h. The reaction was
monitored by increasing the equivalence of t-BuOK, and the
maximum yield was obtained with 1.0 mmol of t-BuOK, and the
starting material was consumed in 4 h as indicated by TLC.
Aer workup and purication by column chromatography, 2-(3-
chlorophenyl)-2,3-dihydroquinazolin-4(1H)-one 3a was isolated
with 90% yield (entries 3 and 4, Table 1), and any increase in the
equivalent of base did not inuence the yield. Bases, like
N-ethyldiisopropylamine, triethylamine, DABCO and DBU, did
not promote the reaction (entries 5–8, Table 1), whereas pyrro-
lidine, morpholine and piperidine gave less yields in 6 h (entries
9–11, Table 1). Both aromatic and heteroaromatic gem-dibro-
momethylarenes bearing various functionalities, such as
chloro, bromo, uoro, methoxy, ester, tert-butyl and triuoro
methyl, –OTHP, –OTBDMS groups, survived the reaction
and provided high yields of corresponding products (Table 2).RSC Adv., 2014, 4, 34479–34486 | 34479
Table 1 Optimization experiments for the synthesis of 3aa
Entry Base Equivalent Temp. (C) Time (h) Yieldb (%) of 3a
1 t-BuOK 0.5 0–25 6 Trace
2 t-BuOK 0.5 80 6 45
3 t-BuOK 1.0 80 4 90
4 t-BuOK 1.5 80 4 89
5 DIPEA 1.0 80 6 —
6 TEA 1.0 80 6 —
7 DABCO 1.0 80 6 —
8 DBU 1.0 80 6 —
9 Pyrrolidine 1.0 80 6 18
10 Morpholine 1.0 80 6 22
11 Piperidine 1.0 80 6 30


































View Article OnlineThe reaction of gem-dibromomethylarenes with 2-amino-
benzamide yielded corresponding 2,3-dihydroquinazolin-4(1H)-
ones, and the proposed reaction mechanism is shown in
Scheme 2.Conclusion
In summary, this is an eﬀective and eﬃcient method of
conversion of substituted 2-aminobenzamide into correspond-
ing 2,3-dihydroquinazolin-4(1H)-ones using gem-dibromome-
thylarenes under mild reaction conditions. The use of gem-
dibromomethylarenes for the direct synthesis of biologically
important 2,3-dihydroquinazolin-4(1H)-ones has been indi-
cated. As this reaction provides 2,3-dihydroquinazolin-4(1H)-
ones in a single step from gem-dibromomethylarenes, it is one
of the easiest pathways for accessing these compounds and the
starting material is easily available. This transformation would
have many applications in synthetic chemistry.Experimental section
General information
Melting points were recorded (uncorrected) on a Buchi Melting
Point B-545 instrument. Infrared (IR) spectra were recorded
using a Jasco FTIR-4100 series. All reagents and solvents used
were commercially procured and used as received. The 1H NMR
spectra were measured on a Bruker DPX-400 at 400 MHz with
TMS as internal standard. The 13C NMR spectra were measured
on a Bruker DPX-400 at 100 MHz. The mass spectra were
recorded on a JEOL JMS-AX505HA mass spectrometer.
Typical procedure for the synthesis of 2-(4-tert-butylphenyl)-
6-chloro-2,3-dihydroquinazolin-4(1H)-one (3f). Potassium tert-34480 | RSC Adv., 2014, 4, 34479–34486butoxide (0.366 g, 0.00327 mol) was added to a suspension of 4-
tertiary butylbenzalbromide (1f) (1 g, 0.00327mol) and 2-amino-
5-chlorobenzamide (2b) (0.614 g, 0.0036 mol) in pyridine–
dimethyl formamide (6.0 : 2.0 mL) solvent mixture. The resul-
tant mixture was heated at 80 C for 4 h. Progress of the reaction
was monitored by TLC. The reaction mass was mixed with water
then extracted with ethyl acetate (2  20 mL), and the organic
phase was washed with brine solution and dried over anhydrous
sodium sulphate. The organic phase was evaporated and the
crude product was puried by column chromatography using
silica gel mesh 100–200 (30% EtOAc in hexane).
2-(3-Chlorophenyl)-2,3-dihydroquinazolin-4(1H)-one (3a).
White solid; m.p. 188.9–189.9 C. (Lit.11 189.8–189.9 C) IR (KBr)
nmax 3290, 3199, 1652, 1613 cm
1. 1H NMR (400 MHz, DMSO-
d6): d 8.42 (s, 1H), 7.63–7.60 (m, 1H), 7.53 (s, 1H), 7.47–7.31 (m,
3H), 7.23–7.27 (m, 2H), 6.77 (d, J ¼ 7.6 Hz, 1H), 6.69 (t, J ¼ 7.6
Hz, 1H), 5.77 (s, 1H) ppm; 13C NMR (100 MHz, DMSO-d6): d
163.9, 147.9, 144.8, 133.9, 133.4, 130.7, 128.7, 127.8, 127.2,
125.8, 117.8, 115.3, 114.9, 66.0 ppm; MS(ESI): m/z ¼ 258.8,
HRMS (ESI): calcd for [C14H13ClN2O + H
+]: 259.7109, found
259.7105.
2,4-Dichloro, 3-dihydroquinazolin-4(1H)-one (3b). White
solid, m.p. 182–184 C (Lit.15 181–185 C); IR (KBr): 3337, 3179,
3025, 1661 cm1. 1H NMR (DMSO-d6, 400 MHz): 8.25 (s, 1H),
7.68–7.65 (m, 3H), 7.50–7.47 (m, 1H), 7.29–7.24 (t, J ¼ 7.5 Hz,
1H), 7.04 (s, 1H), 6.93 (d, J¼ 6.4 Hz, 1H), 6.71 (t, J¼ 8.1 Hz, 1H),
6.1 (s, 1H) ppm; 13C NMR (100 MHz DMSO-d6): d 163.6, 147.5,
136.9, 133.9, 133.5, 132.9, 130.9, 128.9, 128.6, 127.4, 117.6,
114.7, 114.6, 63.3 ppm; MS(ESI): m/z ¼ 293.148, HRMS (ESI):
calcd for [C14H11Cl2N2O + H
+]: 294.1559, found 294.1556.
2-(Pyridin-4-yl)-2,3-dihydroquinazolin-4(1H)-one (3c). Light
yellow solid; m.p.: 187–188 C (lit.8 not reported) IR (KBr): 2922,This journal is © The Royal Society of Chemistry 2014
Table 2 2-Aryl-2,3-dihydro quinazolin-4(1H)-ones results
Entry (Ar) substratea (1) Yield (1) (%) (2) Product (3) Time (h) Yield (3)b,c (%)
1 87 R ¼ –H, R1 ¼ –H, 2a 4 9011
2 84 R ¼ –H, R1 ¼ –H, 2a 4 8815
3 78 R ¼ –H, R1 ¼ –H, 2a 4.5 848
4 80 R ¼ –H, R1 ¼ –H, 2a 4 869
5 81 R ¼ –H, R1 ¼ –H, 2a 4 78


































Table 2 (Contd. )
Entry (Ar) substratea (1) Yield (1) (%) (2) Product (3) Time (h) Yield (3)b,c (%)
6 86 R ¼ Cl, R1 ¼ –H, 2b 4 85
7 84 R ¼ Cl, R1 ¼ –H, 2b 4 86
8 87 R ¼ OMe, R1 ¼ OMe, 2c 4 90
9 1g — R ¼ OMe, R1 ¼ OMe, 2c 4 81
10 77 R ¼ –H, R1 ¼ Cl, 2d 4 78
11 1e — R ¼ –H, R1 ¼ Cl 2d 4 83


































Table 2 (Contd. )
Entry (Ar) substratea (1) Yield (1) (%) (2) Product (3) Time (h) Yield (3)b,c (%)
12 80 R ¼ –H, R1 ¼ Cl, 2d 4 79
13 1f — R ¼ –H, R1 ¼ Cl, 2d 4 85
14 85 R ¼ –H, R1 ¼ Br, 2e 4 88
15 1i — R ¼ –H, R1 ¼ Br, 2e 4 89
16 45 R ¼ –H, R1 ¼ –H, 2a 4 60
17 84 R ¼ –H, R1 ¼ –H, 2a 4 75
a Substrates are prepared from the commercial methyl analogues by radical bromination. b Isolated yields of product (3). c Literature reported
compounds.



































































View Article Online2853, 1674, 1605, cm1. 1H NMR (400 MHz, DMSO-d6): d ¼ 8.88
(d, 2H, J ¼ 6.0 Hz), 8.36 (d, 2H, J ¼ 7.5 Hz), 8.17 (d, 2H, J ¼ 4.5
Hz), 7.88 (d, 2H, J¼ 3.0 Hz), 7.63–7.58 (m, 1H), 5.85 (s, 1H), 5.04
(s, 1H) ppm; 13C NMR (100 MHz, DMSO-d6): d ¼ 160.93, 147.98,
146.88, 132.95, 126.34, 125.84, 124.46, 120.22, 69.15 ppm;
MS(ESI):m/z¼ 225.245. HRMS (ESI): calcd for [C13H12N3O + H+]:
226.2539. Found 226.2535.
Methyl 4-(4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)benzoate
(3d). White solid; m.p.: 200.2–202.4; (lit.9 199.2–202.3 C). IR
(KBr): 3328, 3025, 2930, 1760, 1610 cm1. 1H NMR (400 MHz,
DMSO-d6): d 8.40 (s, 1H), 7.97 (d, J ¼ 8.3 Hz, 2H), 7.64–7.57 (m,
3H), 7.28–7.22 (m, 2H), 6.75 (d, J ¼ 7.5 Hz 1H), 6.68 (td, J ¼ 7.5,
1.0 Hz, 1H), 5.84 (t, J ¼ 2.1 Hz, 1H), 3.85 (s, 3H) ppm; 13C NMR
(100 MHz, DMSO-d6): d 165.91, 163.36, 147.50, 146.94, 133.40,
129.56, 129.22, 129.22, 127.33, 127.14, 127.14, 117.26, 114.86,
114.43, 65.88, 52.16 ppm; MS(ESI): m/z ¼ 282.294, HRMS (ESI)
calcd for [C16H15N2O3 + H
+]: 283.3019, found 283.3015.
2-(5-Phenylpyridin-2-yl)-2,3-dihydroquinazolin-4(1H)-one (3e).
Light yellow solid; m.p.: 185–186 C; IR (KBr) nmax 3184.26,
3066.61, 2929.67, 1666.38, 1610.45 cm1. 1H NMR (400 MHz,
DMSO-d6): d 8.66–8.64 (d, J ¼ 4.8 Hz, 1H), 8.32 (s 1H), 8.09–8.07
(d, J ¼ 8.4 Hz, 2H), 7.95–7.93 (d, J ¼ 8 Hz, 1H), 7.88–7.84 (tt,
J ¼ 1.6 Hz, 1H), 7.62–7.58 (m 3H), 7.35–7.32 (m, 1H), 7.26–7.22
(tt, J¼ 8.4 Hz, 1H), 7.15 (s, 1H), 6.76–6.74 (d, J¼ 8 Hz, 1H), 6.69–
6.52 (tt, J ¼ 8 Hz, 1H), 5.8 (s, 1H) ppm; 13C NMR (100 MHz,
DMSO-d6): d 163.52, 155.57, 149.54, 147.76, 142.41, 138.8, 137.2,
133.3, 127.34, 127.22, 126.45, 122.68, 120.29, 117.13, 114.97,
114.42, 66.18 ppm; MS(ESI): m/z ¼ 301.122, HRMS (ESI) calcd
for [C19H15N3O + H
+] 302.3498, found 302.3495.
2-(4-tert-Butylphenyl)-6-chloro-2,3-dihydroquinazolin-4(1H)-
one (3f). Light yellow solid; m.p.: 180–182 C; IR (KBr) nmax
3328.91, 3257.55, 2929.67, 1741.60, 1612.38 cm1.1H NMR (400
MHz, DMSO-d6): d 8.38 (s, 1H), 7.53–7.52 (d, J¼ 2.4 Hz, 1H), 7.42–
7.38 (m, 4H), 7.27–7.24 (m, 2H), 6.75–6.73 (d, J¼ 8.4 Hz, 1H), 5.73
(s, 1H), 1.26 (S, 9H) ppm; 13C NMR (100 MHz, DMSO-d6):
d 162.40, 151.13, 146.62, 138.18, 132.96, 126.59, 126.35, 126.20,
125.11, 120.61, 116.31, 116, 66.27, 34.28, 31.04 ppm; MS(ESI):
m/z ¼ 314.119. HRMS (ESI) calcd for [C18H20ClN2O + H+]
315.8172 found 315.8170.34484 | RSC Adv., 2014, 4, 34479–344866-Chloro-2-(3,4,5-trimethoxyphenyl)-2,3-dihydroquinazolin-
4(1H)-one (3g). White solid; m.p.: 158–160 C. IR (KBr) nmax
3274.90, 3197.76, 2964.39, 2929.67, 1654, 1612.33 cm1. 1H
NMR (400 MHz, DMSO-d6): d 8.36 (s, 1H), 7.54–7.53 (d, J ¼ 2.4
Hz, 1H), 7.29–7.24 (m, 2H), 6.82–6.77 (m, 4H), 5.72 (S, 1H), 3.76
(s, 6H), 3.64 (s, 3H) ppm; 13C NMR (100 MHz, DMSO-d6): d
162.49, 152.76, 146.73, 137.69, 136.17, 133.02, 126.40, 120.86,
116.42, 116.12, 104.45, 66.73, 59.95, 59.71, 55.92 ppm; MS(ESI):
m/z ¼ 348.088, HRMS (ESI) calcd for [C17H18ClN2O4 + H+]
349.7888, found 349.7885.
6,7-Dimethoxy-2-(4-(triuoromethyl)phenyl)-2,3-dihydro-
quinazolin-4(1H)-one (3h). Light yellow solid; m.p.: 188–189 C;
IR (KBr) nmax 3301.91, 3197.76, 2925.81, 2852.52, 1649.02,
1618.17 cm1; 1H NMR (400 MHz, DMSO-d6): d 8.18 (s, 1H),
7.75–7.67 (m, 4H), 7.08 (s, 1H), 6.91 (s, 1H), 6.35 (s, 1H), 5.77 (s,
1H), 3.72 (s, 3H), 3.65 (S, 3H) ppm; 13C NMR (100 MHz, DMSO-
d6): d 163.44, 153.93, 146.60, 143.07, 141.58, 127.74, 127.54,
125.18, 125.15, 125.04, 109.74, 106.62, 97.99, 65.92, 55.74, 55.34
ppm; MS(ESI): m/z ¼ 352.307, HRMS (ESI) calcd for
[C17H16F3N2O3 + H
+] 353.3157, found 353.3155.
6,7-Dimethoxy-2-(3,4,5-trimethoxyphenyl)-2,3-dihydro-
quinazolin-4(1H)-one (3i). Light red solid; m.p.: 242–244 C. IR
(KBr) nmax 3353.98, 3197.76, 2937.38, 2837.09, 1654.81, 1620.09,
cm1. 1H NMR (400 MHz, DMSO-d6): d 7.49 (s, 1H), 7.13 (s, 1H),
6.85 (s, 2H), 6.7 (s, 1H), 6.4 (s, 1H), 5.64 (s, 1H), 3.78 (s, 3H) ppm;
13C NMR (100 MHz, DMSO-d6): d 163.82, 153.78, 152.83, 152.64,
143.75, 141.55, 137.48, 136.52, 109.79, 108.24, 104.96, 104.80,
97.99, 67.30, 59.91, 55.87, 55.77, 55.69, 55.35 ppm; MS(ESI): m/z
¼ 374.387, HRMS (ESI) calcd for [C19H23N2O6 + H+] 375.3957,
found 375.3954.
2-(2-Bromo-5-chlorophenyl)-7-chloro-2,3-dihydroquinazolin-
4(1H)-one (3j). White solid; m.p.: 197–198 C; IR (KBr) nmax
3353.98, 3288.4, 3182.33, 3051.18, 2921.96, 2854.45, 1694.02,
1610.45 cm1; 1H NMR (400 MHz, DMSO-d6): d 8.33 (s, 1H), 7.74–
7.7 (m, 1H), 7.63 (s, 1H), 7.41–7.38 (dd, J ¼ 2.6 Hz, 1H), 7.29–7.22
(m, 2H), 6.81–6.8 (d, J¼ 1.2 Hz, 1H), 6.75–6.72 (dd, J¼ 1.8 Hz, 1H),
6.1 (s, 1H) ppm; 13C NMR (100 MHz, DMSO-d6): d 162.57, 160.13,
148.35, 141.02, 138.01, 134.65, 129.35, 117.92, 117.6, 116.58,





































one (3k). Brown solid; m.p.: 208–210 C; IR (KBr) nmax 3193.9,
3068.53, 2923.88, 2854.45, 2813.95, 1666.38, 1610.45 cm1; 1H
NMR (400 MHz, DMSO-d6): d 8.66–8.65 (d, J ¼ 4.4 Hz, 1H), 8.45
(s, 1H), 8.11–8.09 (d, J ¼ 8.4 Hz, 1H), 7.95–7.93 (d, J ¼ 8 Hz,
1H), 7.89–7.84 (tt, J ¼ 1.46 Hz, 1H), 7.62–7.56 (m, 4H), 7.43 (s,
1H), 7.36–7.33 (m, 1H), 6.8–6.79 (d, J ¼ 2 Hz, 1H), 6.69–6.67
(dd, J ¼ 2 Hz, 1H), 5.86 (s, 1H) ppm; 13C NMR (100 MHz,
DMSO-d6): d 162.63, 155.48, 149.53, 148.66, 142.04, 138.94,
137.81, 137.37, 137.21, 129.32, 128.35, 127.1, 126.54, 122.69,
120.29, 117.04, 113.62, 113.42, 66.07 ppm; MS(ESI): m/z ¼




one (3l). Light yellow solid; m.p.: 208–210 C; IR (KBr) nmax
3330.84, 3298.05, 3234.4, 3060.82, 2962.46, 2867.95, 1643.24,
1610.45 cm1; 1H NMR (400 MHz, DMSO-d6): d 8.11 (s, 1H),
7.61–7.59 (d, J ¼ 8.4 Hz, 1H), 7.04 (s, 1H), 6.99–6.96 (m, 1H),
6.9–6.87 (m, 2H), 6.817–6.813 (d, J ¼ 1.6 Hz, 1H), 6.67–6.65 (dd,
J ¼ 2 Hz, 1H), 5.99 (s, 1H), 3.77 (s, 3H), 3.66 (s, 3H) ppm; 13C
NMR (100 MHz, DMSO-d6): d 162.91, 152.85, 150.36, 148.71,
137.74, 129.58, 129.21, 124.74, 116.92, 113.61, 113.5, 113.34,
112.24, 61.07, 55.99, 55.36 ppm; MS(ESI): m/z ¼ 318.754.




one (3m). Light yellow solid; m.p.: 110–112 C; IR (KBr) nmax
3332.76, 3170.76, 3031.89, 2925.81, 2831.31, 1656.74, 1608.52
cm1; 1H NMR (400MHz, DMSO-d6): d 8.31 (s, 1H), 8.14–8.1 (dd,
J ¼ 2.6 Hz, 1H), 7.6–7.38 (m, 4H), 7.3 (s, 1H), 6.757–6.752 (d, J ¼
2 Hz, 1H), 6.67–6.65 (dd, J ¼ 2 Hz, 1H), 5.75 (s, 1H) ppm; 13C
NMR (100 MHz, DMSO-d6): d 162.71, 151.17, 148.8, 138.24,
137.72, 129.13, 127.68, 126.55, 125.43, 125.3, 116.9, 113.6,
113.31, 66.33, 34.29, 31.04, 30.84 ppm; MS(ESI): m/z ¼ 314.809,




one (3n). White solid; m.p.: 137–138 C; IR (KBr) nmax 3298.26,
3182.33, 3070.46, 2956.67, 2923.67, 2923.88, 2852.52, 1700,
1610 cm1; 1H NMR (400 MHz, DMSO-d6): d 8.38 (s, 1H), 7.52–
7.49 (m, 3H), 7.33 (s, 1H), 7.24–7.2 (m, 1H), 6.94–6.93 (d, J ¼ 2
Hz, 1H), 6.83–6.80 (dd, J ¼ 1.8 Hz, 1H), 5.81 (s, 1H), 3.68 (s, 6H)
ppm; 13C NMR (100 MHz, DMSO-d6): d 162.65, 148.42, 141.06,
134.75, 129.42, 127, 120.44, 118.16, 117.94, 116.63, 115.98,
115.74, 113.57, 66.20, 55.42, 55.36 ppm; MS(ESI):m/z¼ 363.205,




4(1H)-one (3o). White solid; m.p.: 206–207 C; IR (KBr) nmax
3294.36, 3194.33, 3074.5, 2958.67, 2926.86, 2854.53, 1705.1,
1605 cm1; 1H NMR (400 MHz, DMSO-d6): d 8.34 (s, 1H), 7.74–
7.7 (m, 1H), 7.57–7.55 (d, J ¼ 8.4 Hz, 1H), 7.40–7.37 (dd, J ¼ 3.2
Hz, 1H),7.28–7.23 (m, 2H), 6.963–6.960 (d, J¼ 1.2 Hz, 1H), 6.89–
6.86 (dd, J ¼ 1.8 Hz, 1H), 6.09 (s, 1H) ppm; 13C NMR (100 MHz,
DMSO-d6): d 162.69, 160.91, 148.74, 137.49, 129.39, 128.95,This journal is © The Royal Society of Chemistry 2014126.82, 125.16, 119.96, 116.40, 115.28, 115.07, 113.88, 65.75
ppm; MS (ESI): m/z ¼ 400.04, HRMS (ESI) calcd for [C14H10-
Br2FN2O + H
+] 401.0484, found 401.0481.
2-(4-(Tetrahydro-2H-pyran-2-yloxy)phenyl)-2,3-dihydroquinazolin-
4(1H)-one (3p). White solid; m.p.: 136–138 C; IR (KBr) nmax
3327, 3028, 2932, 1738, 1615 cm1; 1H NMR (400 MHz, DMSO-
d6): d 8.16 (s, 1H), 7.59–7.57 (d, J ¼ 8 Hz, 1H), 7.39–7.37 (d, J ¼ 8
Hz, 2H), 7.23–7.19 (t, J ¼ 7.6 Hz, 1H), 7.02–6.98 (m, 3H), 6.72–
6.63 (m, 2H) 5.67 (s, 1H), 5.45 (s, 1H), 3.72–3.67 (m, 1H), 3.52–
3.48 (m, 1H), 1.88–1.69 (m, 3H), 1.60–1.48 (m, 4H) ppm; 13C
NMR (100 MHz, DMSO-d6): 164.13, 157.07, 148.43, 134.88,
134.86, 133.69, 128.54, 127.78, 117.52, 116.63, 115.39, 114.83,
96.04, 66.79, 61.91, 30.21, 25.11, 18.98 ppm; MS (ESI): 324.14,




4(1H)-one (3q). White solid; m.p.: 139–141 C; IR (KBr) nmax
3329.86, 3032.60, 2928.72, 1740.30, 1612.30 cm1; 1H NMR (400
MHz, DMSO-d6): d 8.17 (s, 1H), 7.64–7.62 (dd, J ¼ 1.6 Hz, 1H),
7.41–7.39 (dd, J ¼ 2 Hz, 2H), 7.28–7.24 (m, IH), 7.02 (s, 1H),
6.89–6.87 (dd, J ¼ 2 Hz, 2H), 6.77–6.75 (d, J ¼ 8.4 Hz, 1H) 6.71–
6.67 (m, 1H), 5.72 (s, 1H), 1.02–0.92 (m, 9H), 0.25–0.15 (m, 6H)
ppm; 13C NMR (100 MHz, DMSO-d6): 164.07, 155.77, 148.45,
134.8, 133.69, 128.78, 127.77, 119.97, 117.50, 115.32, 114.81,
66.85, 26.0, 18.38, 4.08 ppm; MS (ESI): 354.17, HRMS (ESI)
calcd for [C20H26N2O2Si + H
+] 355.1852, found 358.1948.Acknowledgements
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